Post-bombesin decorated nanostructured lipid carriers (NLC) exhibited more stability and markedly higher transfection efficiency and better anti-tumor activity than pre-bombesin decorated NLC for lung cancer therapy, both in vitro and in vivo [248]. The gene discussed is GRP; the disease is neoplasm.